» Articles » PMID: 16806004

[Immune Response and Protective Efficacy Induced by Fusion Protein ESAT6-CFP10 of M.tuberculosis in Mice]

Overview
Date 2006 Jun 30
PMID 16806004
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To study murine humoral and cellular immune response induced by fusion protein ESAT6-CFP10 and to examine its protective efficacy against M. tuberculosis (MTB) in mice.

Methods: BALB/c mice were immunized subcutaneously on the back with fusion protein ESAT6-CFP10 that was transferred to nitro cellulose (NC) membrane beforehand. Stimulation index (SI) of the spleen lymphocytes of the immunized mice was measured by MTT colorimetry. The level of IFN-gamma and IL-2 and CTL upon antigen-specific stimulation were detected. The vaccinated BALB/c mice were intravenously infected with MTB H37Rv (10(5) CFU/mouse). Four weeks later the number of CFU in spleens was determined.

Results: The titer of serum specific antibody in BALB/c mice immunized with fusion protein ESAT6-CFP10 was 1:6,400. The SI of fusion protein immunized group (1.90+/-0.15) was significantly higher than that of saline-immunized group (0.9+/-0.15). The level of IFN-gamma and IL-2 induced by the fusion protein was 1.792+/-19 ng/L and 0.211+/-11 ng/L respectively, which was significantly higher than that of saline-immunized group and lower than that of BCG-immunized group. The specific killing activity of splenocytes was 36%. Compared with the saline-immunized mice (bacterial load was 6.51+/-0.13), MTB number (bacterial load was 5.24+/-0.15) was reduced dramatically in the spleens of BALB/c mice immunized with the fusion protein, but the protective efficacy of the mice immunized with BCG was higher than that of ESAT6-CFP10 vaccinated group.

Conclusion: Fusion protein ESAT6-CFP10 can be used as a candidate for novel vaccines.

Citing Articles

Chemical and Biological Characterization of Mycobacterium Tuberculosis-Specific ESAT6-Like Proteins and their Potentials in the Prevention of Tuberculosis and Asthma.

Mustafa A Med Princ Pract. 2023; .

PMID: 37703836 PMC: 10659698. DOI: 10.1159/000534002.


Tuberculosis vaccine research in China.

Lowrie D Emerg Microbes Infect. 2015; 1(7):e7.

PMID: 26038419 PMC: 3636423. DOI: 10.1038/emi.2012.3.


In silico analysis and experimental validation of Mycobacterium tuberculosis -specific proteins and peptides of Mycobacterium tuberculosis for immunological diagnosis and vaccine development.

Mustafa A Med Princ Pract. 2013; 22 Suppl 1:43-51.

PMID: 24008694 PMC: 5586813. DOI: 10.1159/000354206.


Cellular immune responses to recombinant Mycobacterium bovis BCG constructs expressing major antigens of region of difference 1 of Mycobacterium tuberculosis.

Shaban K, Amoudy H, Mustafa A Clin Vaccine Immunol. 2013; 20(8):1230-7.

PMID: 23761657 PMC: 3754513. DOI: 10.1128/CVI.00090-12.


Improved sensitivity of diagnosis of tuberculosis in patients in Korea via a cocktail enzyme-linked immunosorbent assay containing the abundantly expressed antigens of the K strain of Mycobacterium tuberculosis.

Shin A, Shin S, Lee K, Eom S, Lee S, Lee B Clin Vaccine Immunol. 2008; 15(12):1788-95.

PMID: 18945883 PMC: 2593165. DOI: 10.1128/CVI.00231-08.